Daisy Philips

TL;DR: Cancer exome–guided analysis of T-cell reactivity in this patient revealed reactivity against two neoantigens, including a dominant T- cell response against a mutant epitope of the ATR (ataxia telangiectasia and Rad3 related) gene product that increased strongly after ipilimumab treatment.

TL;DR: It is found that neoadjuvant ipilimumab + nivolumab expand more tumor-resident T cell clones than adjuvant application, and warrants future evaluation with modified dosing schedules to reduce treatment-related adverse events.

TL;DR: A rapid search in PubMed shows that using "flow cytometry immunology" as a search term yields more than 68 000 articles, the first of which is not about lymphocytes as mentioned in this paper.

TL;DR: The observation that anti–CTLA-4 treatment induces a significant number of newly detected T cell responses—but only infrequently boosts preexisting immune responses—provides strong evidence for anti-CTla-4 therapy–enhanced T cell priming as a component of the clinical mode of action.

TL;DR: Using multiday intravital imaging, it is demonstrated that T cell recognition of a minor fraction of tumor cells leads to sensing of IFNγ by a large part of the tumor mass, revealing how, through IFNα, CD8+ T cells modulate the behavior of remote tumor cells, including antigen-loss variants.